These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 28544814)
1. Optimization of liposomal topotecan for use in treating neuroblastoma. Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814 [TBL] [Abstract][Full Text] [Related]
2. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer. Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060 [TBL] [Abstract][Full Text] [Related]
3. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization. Gilabert-Oriol R; Chernov L; Anantha M; Dragowska WH; Bally MB Drug Deliv Transl Res; 2017 Aug; 7(4):544-557. PubMed ID: 28432657 [TBL] [Abstract][Full Text] [Related]
4. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity. Li C; Wang C; Yang H; Zhao X; Wei N; Cui J J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269 [TBL] [Abstract][Full Text] [Related]
5. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer. Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316 [TBL] [Abstract][Full Text] [Related]
6. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats. Dadashzadeh S; Vali AM; Rezaie M Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511 [TBL] [Abstract][Full Text] [Related]
7. DMPC/Chol liposomal copper CX5461 is therapeutically superior to a DSPC/Chol formulation. Leung AWY; Chen KTJ; Ryan GM; Anantha M; Wretham N; Nosrati Z; Heroux D; Wang L; Chow N; Dai Z; Bally MB J Control Release; 2022 May; 345():75-90. PubMed ID: 35259461 [TBL] [Abstract][Full Text] [Related]
8. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes. Zucker D; Barenholz Y J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223 [TBL] [Abstract][Full Text] [Related]
9. Copper-topotecan complexation mediates drug accumulation into liposomes. Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880 [TBL] [Abstract][Full Text] [Related]
10. Multipronged, strategic delivery of paclitaxel-topotecan using engineered liposomes to ovarian cancer. Jain A; Jain SK Drug Dev Ind Pharm; 2016 Jan; 42(1):136-149. PubMed ID: 26006330 [TBL] [Abstract][Full Text] [Related]
11. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator? Cui J; Li C; Wang C; Li Y; Zhang L; Zhang L; Xiu X; Li Y; Wei N Int J Pharm; 2010 Oct; 399(1-2):31-6. PubMed ID: 20678563 [TBL] [Abstract][Full Text] [Related]
12. Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. Lim HJ; Masin D; Madden TD; Bally MB J Pharmacol Exp Ther; 1997 Apr; 281(1):566-73. PubMed ID: 9103545 [TBL] [Abstract][Full Text] [Related]
13. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. Krishna R; Webb MS; St Onge G; Mayer LD J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822 [TBL] [Abstract][Full Text] [Related]
14. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. Li N; Song Y; Du P; Shen Y; Yang J; Gui L; Wang S; Wang J; Sun Y; Han X; Shi Y Biomed Pharmacother; 2013 Oct; 67(8):801-6. PubMed ID: 24074809 [TBL] [Abstract][Full Text] [Related]
15. Preparation, optimization, and characterization of topotecan loaded PEGylated liposomes using factorial design. Vali AM; Toliyat T; Shafaghi B; Dadashzadeh S Drug Dev Ind Pharm; 2008 Jan; 34(1):10-23. PubMed ID: 18214751 [TBL] [Abstract][Full Text] [Related]
16. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968 [TBL] [Abstract][Full Text] [Related]
17. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer. Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767 [TBL] [Abstract][Full Text] [Related]
18. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Sottile F; Gnemmi I; Cantilena S; D'Acunto WC; Sala A Oncotarget; 2012 May; 3(5):535-45. PubMed ID: 22619121 [TBL] [Abstract][Full Text] [Related]
19. Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models. Tardi P; Choice E; Masin D; Redelmeier T; Bally M; Madden TD Cancer Res; 2000 Jul; 60(13):3389-93. PubMed ID: 10910044 [TBL] [Abstract][Full Text] [Related]
20. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent. Wehbe M; Anantha M; Shi M; Leung AW; Dragowska WH; Sanche L; Bally MB Int J Nanomedicine; 2017; 12():4129-4146. PubMed ID: 28615941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]